Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Worth Up to $464m Advances MEI Drug, Diversifies Helsinn's Portfolio

Executive Summary

Helsinn will help MEI Pharma advance its HDAC inhibitor pracinostat into Phase III development via a partnership worth up to $464m.

You may also be interested in...



Deal Watch: AZ Ups mRNA Stake, Gilead's HIV Innovation, Hospira Returns Lucentis Biosimilar, Pfizer/Takeda End Distribution Deal

Deal activity over the past week saw AstraZeneca stealthily increase its commitment to mRNA player Moderna, Gilead seek innovation in HIV through an alliance with Genmab for its bispecific antibody technology, and Hospira back out of a licensing deal for Pfenex's Lucentis biosimilar, and more.

Keeping Track: Opana ER Abuse Deterrence Claim Withdrawn; Third Neulasta Biosimilar Submitted; Keytruda Cleared In Head And Neck Cancer

The latest drug development news and highlights from our FDA Performance Tracker.

Case Studies: How Three Public Companies Financed R&D In A Tough Market

The market for public offerings by biopharma companies is tough, but Corbus Pharmaceuticals, Loxo Oncology and Novavax used three different strategies to raise cash from new and existing shareholders.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

ID1124690

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel